<- Go Home
Greenwich LifeSciences, Inc.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Market Cap
$183.2M
Volume
35.8K
Cash and Equivalents
$5.8M
EBITDA
-$10.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$21.44
52 Week Low
$8.00
Dividend
N/A
Price / Book Value
36.77
Price / Earnings
-17.19
Price / Tangible Book Value
36.79
Enterprise Value
$177.4M
Enterprise Value / EBITDA
-16.49
Operating Income
-$10.8M
Return on Equity
151.72%
Return on Assets
-89.85
Cash and Short Term Investments
$5.8M
Debt
N/A
Equity
$5.0M
Revenue
N/A
Unlevered FCF
-$3.8M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium